RxDoctor Payments Data

Steven Goldberg, MD

Cardiovascular Disease · Great Neck, NYNPI 1205839255

Payments from drug & device makers

$90,241in general payments, 2019–2025

Across 320 payments — averaging $282.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$35K
  • Esperion Therapeutics, Inc.$19K
  • Cleerly, Inc.$12K
  • AstraZeneca$10K
  • Lilly USA, LLC$6K
  • Abbott$926
  • plus $6K from 24 others

What the payments were for

  • Consulting fees$4,0085%
  • Speaking & faculty fees$63,22381%
  • Travel & lodging$1540%
  • Food & beverage$10,56414%
  • Education$440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim38$34,849
Esperion Therapeutics, Inc.23$19,481
Cleerly, Inc.1$12,250
AstraZeneca19$10,379
Lilly USA, LLC11$5,948
Abbott13$926
Boston Scientific14$895
E.r. Squibb & Sons, L.L.C.23$763
Johnson & Johnson39$691
Novartis36$562
Pfizer27$480
Medtronic4$441
Heartflow, Inc.4$427
Novo Nordisk22$333
Edwards Lifesciences2$319
Amgen13$281
Cvrx, Inc.2$243
Biohaven Pharmaceuticals, Inc.2$213
Alnylam Pharmaceuticals Inc.1$123
AbbVie8$120
GSK1$116
Merck4$111
Regeneron Healthcare Solutions, Inc.3$68
Althera Pharmaceuticals LLC3$59
Sanofi-aventis U.S. LLC2$46
Bardy Diagnostics, Inc.1$39
Terumo Medical Corporation1$38
Coala Life Inc1$24
Lundbeck LLC1$13
Vivaquant Inc, Dba Rhythm Express1$6

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,241 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$950,463
Medicare patients
1,363
Services billed
19,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban159$135,140
OzempicSemaglutide118$112,507
MounjaroTirzepatide74$99,230
XareltoRivaroxaban70$90,843
JardianceEmpagliflozin58$76,780
RybelsusSemaglutide43$51,987
EntrestoSacubitril/Valsartan44$49,055
FarxigaDapagliflozin Propanediol46$48,246
Repatha SureclickEvolocumab52$35,205
JanuviaSitagliptin Phosphate22$28,661
NexlizetBempedoic Acid/Ezetimibe19$18,440
NexletolBempedoic Acid32$17,285
Metoprolol Succinate525$9,146
Ezetimibe235$7,434
Sildenafil Citrate17$5,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$333$164,494161 claims
PfizerEliquis$480$135,140159 claims
Lilly USA, LLCMounjaro$5,948$99,23074 claims
Johnson & JohnsonXarelto$691$90,84370 claims
Boehringer IngelheimJardiance$34,849$76,78058 claims
NovartisEntresto$562$49,05544 claims
AstraZenecaFarxiga$10,379$48,24646 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$19,481$35,72551 claims
MerckJanuvia$111$28,66122 claims
AbbVieSynthroid$120$2,84636 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →